Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of TRK-820 in Hemodialysis Patients
NCT03002233Phase 1Completed
- Sponsor
- Toray Industries
- Start
- Nov 2016
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of nalfurafine in uremic pruritus, sponsored by Toray Industries. Primary endpoints: Area under the time curve from time zero to 24 hours postdose, Area under the time curve from time zero to the last quantifiable concentration at 60 hours and 10 more. Started Nov 2016; status: completed.
02
Drugs
nalfurafine
03
Conditions
uremic pruritus
Beyond the preview
Go deeper on NCT03002233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03002233.